Jun 22, 2020
Regeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation
Jun 19, 2020
FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
Jun 19, 2020
Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Jun 17, 2020
ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron
Jun 11, 2020
Two Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants
Jun 11, 2020
Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
Jun 08, 2020
Regeneron Announces Virtual-Only Format for 2020 Annual Meeting of Shareholders
Jun 01, 2020
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
May 29, 2020
Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
May 26, 2020
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
May 25, 2020
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
May 13, 2020
Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio
May 11, 2020
Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
May 05, 2020
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Apr 29, 2020
Regeneron Announces Upcoming Investor Conference Presentations
Apr 27, 2020
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
Apr 27, 2020
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
Apr 24, 2020
Sanofi at forefront of fight against COVID-19 in Q1 2020
Apr 19, 2020
Innovent Biologics Announces FDA Approval of Pemazyre(TM) (Pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Apr 16, 2020
FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola